The global insulin delivery devices market size was estimated at USD 28.06 billion in 2030 and is expected to grow at a CAGR of 7.89% from 2024 to 2030. Obesity, sedentary lifestyles, and unhealthy food habits, primarily in the young population, lead to the occurrence of diabetes. In addition, the growing diabetic geriatric population is another factor supporting the growth of this vertical. According to the United Nations, Department of Economic and Social Affairs, around 901 million individuals were aged 60 or over in 2015 and this number is projected to increase to 1.4 billion by 2030. Thus, the enlarging elderly population is expected to boost the demand for insulin delivery devices.
Technological innovations and advancements are an ongoing trend in this vertical. The high demand for advanced insulin delivery devices is supporting the adoption of recently launched innovative pen devices and portable pumps, which is estimated to boost the market growth. Also, favorable reimbursement policies for these devices, mainly in developed countries like the U.S. and Germany, are anticipated to fuel the market growth during the study period. However, stringent regulatory requirements regulating the approval of insulin delivery devices and the high cost of insulin analogs in diabetes care management are major factors restraining the growth of this industry.
The market's prominent competitors are taking different initiatives such as acquisition, funding, and product development to expand their product portfolio and enhance their manufacturing capacity. For instance, in October 2021, Eli Lilly partnered with Cipla, to market its Insulin products (Humalog and Trulicity) in India. Additionally, In June 2021, the company acquired Protomer Technologies, to strengthen its market presence. Further, Novo Nordisk, joined hands with Biocorp to develop a Bluetooth-enabled smart add-on device for their pen insulin injector.
Request a free sample copy or view the report summary: Insulin Delivery Devices Market Report
The insulin pens segment was the largest revenue-generating category of this market in 2021. The pen is equipped with self-contained cartridges and offers ease in handling and less pain while injecting insulin. The advantages of these pen devices over other products are resulting in their growing popularity, thus serving as a vital factor in contributing to the sectorb s highest share in this market
The home care segment is estimated to be the fastest-growing segment due to increased adoption of self-care diabetes management devices and the availability of simplified and user-friendly product designs for patients
North America is the leading regional sector and accounted for the largest revenue share in 2021 primarily due to the favorable reimbursement scenario in this space. Also, the presence of major manufacturers in this region is supporting market growth
In Asia Pacific, the market is anticipated to grow fast during the forecast period. The high prevalence rate of diabetes in countries, such as China and India, is a major factor contributing to market expansion in this region
Grand View Research has segmented the global insulin delivery devices market report based on product, end use, and region.
Insulin Delivery Devices Product Outlook (Revenue, USD Million, 2018 - 2030)
Insulin Pens
Reusable Insulin Pens
Disposable Insulin Pens
Insulin Pumps
Patch Pumps
Tethered Pumps
Insulin Pen Needles
Standard Pen Needles
Safety Pen Needles
Insulin Syringes
Other Products
Insulin Delivery Devices End Use Outlook (Revenue, USD Million, 2018 - 2030)
Hospitals & Clinics
Homecare
Other End Users
Insulin Delivery Devices Regional Outlook (Revenue, USD Million, 2018 - 2030)
North America
U.S.
Canada
Mexico
Europe
UK
Germany
France
Italy
Spain
Denmark
Sweden
Norway
Asia Pacific
Japan
China
India
Australia
Thailand
South Korea
Latin America
Brazil
Argentina
Middle East & Africa
South Africa
Saudi Arabia
UAE
Kuwait
List of Key Players in Insulin Delivery Devices Market
Novo Nordisk A/S
Sanofi
Eli Lilly and Company
Ypsomed AG
Medtronic
Insulet Corporation
B. Braun SE
Owen Mumford Ltd.
Tandem Diabetes Care, Inc.
BD (Becton, Dickinson, and Company)
"The quality of research they have done for us has been excellent..."